Showing results (111-120 of 923) with videos related to
Sort By:
Pageof 93
Biotechnology and Bioengineering|January 29, 2000
Part I. Bcl-2 and Bcl-x(L) limit apoptosis upon infection with alphavirus vectorsA J Mastrangelo, J M Hardwick, F Bex, et al.Biotechnology and Bioengineering|September 15, 1999
Antiapoptosis chemicals prolong productive lifetimes of mammalian cells upon Sindbis virus vector infectionA J Mastrangelo, S Zou, J M Hardwick, et al.Biotechnology and Bioengineering|January 29, 2000
Part II. Overexpression of bcl-2 family members enhances survival of mammalian cells in response to various culture insultsA J Mastrangelo, J M Hardwick, S Zou, et al.Clinical Cardiology|May 10, 2000
Impact of left ventricular size on pharmacologic reverse remodeling in heart failureT B Levine, A B Levine, J Bolenbaugh, et al.Clinical Cardiology|December 16, 1998
The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor-nitrate therapy in heart failureT B Levine, A B Levine, S J Keteyian, et al.Journal of Women'S Health & Gender-Based Medicine|July 7, 2000
Reversal of heart failure remodeling in womenT B Levine, A B Levine, P Kaminski, et al.Journal of Virology|June 1, 1995
Apoptosis as a cause of death in measles virus-infected cellsL M Esolen, S W Park, J M Hardwick, et al.The Journal of Experimental Medicine|August 4, 1999
Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcriptionR K Srivastava, C Y Sasaki, J M Hardwick, et al.Proceedings of the National Academy of Sciences of the United States of America|March 31, 1999
Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosisR K Srivastava, Q S Mi, J M Hardwick, et al.Journal of Virology|September 1, 1992
The Epstein-Barr virus R transactivator (Rta) contains a complex, potent activation domain with properties different from those of VP16J M Hardwick, L Tse, N Applegren, et al.Pageof 93